Inclusion Criteria:

- Histologic proof of malignancy (including non-Hodgkin's lymphoma and multiple
myeloma)

- Patients must have measurable or evaluable disease; patients with reliable tumor
markers (as determined by protocol chairman) are eligible for participation

- ANC >= 1000/uL

- PLT >= 50,000/uL

- Total bilirubin =< 1.5 x upper limit of normal (ULN)

- AST =< 2.5 x ULN or AST =< 5 x ULN if liver involvement

- Patients with abnormal kidney function will be allowed and will be grouped
accordingly

- Willingness to return to treating institution for follow-up

- Life expectancy >= 12 weeks

- Willingness to provide all biologic specimens as required by the protocol

Exclusion Criteria:

- Known standard therapy for the patient's disease that is potentially curative or
definitely capable of extending life expectancy

- ECOG performance status (PS) 3 or 4

- Uncontrolled intercurrent illness including but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Any of the following prior therapies:

- Chemotherapy ≤ 4 weeks

- Mitomycin C/nitrosoureas ≤ 6 weeks

- Immunotherapy ≤ 4 weeks

- Biologic therapy ≤ 4 weeks

- Radiation therapy ≤ 2 weeks

- Radiation to > 50 % of bone marrow (excepting patients who have had total body
irradiation incorporated into bone marrow or stem cell transplantation; all
other eligibility criteria still apply)

- PS-341 treatment

- Failure to fully recover from effects of prior chemotherapy regardless of interval
since last treatment (excludes renal function)

- New York Heart Association classification III or IV

- Symptomatic CNS metastases; patients who have received definitive treatment for brain
metastases (radiation and/or surgery) and are stable for >= 8 weeks are eligible;
eligible patients with brain metastases should not be taking enzyme-inducing
anticonvulsants and should be receiving stable doses of steroids

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception (condoms, diaphragm, birth control pills, injections, intrauterine
device [IUD], or abstinence, etc.)

- This study involves an investigational agent whose genotoxic, mutagenic and
teratogenic effects on the developing fetus and newborn are unknown

- Other concurrent chemotherapy, immunotherapy, or radiotherapy

- HIV-positive patients receiving anti-retroviral therapy (HAART); there is a potential
for pharmacokinetic interactions

- Concurrent use of other investigational agent (including thalidomide); bisphosphonate
therapy (e.g. pamidronate or zoledronate) will not be considered investigational
agents for the purpose of trial eligibility

- Pre-existing grade >= 2 neuropathy